These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 20924183)

  • 1. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.
    Małek LA; Przyłuski J; Spiewak M; Kłopotowski M; Kostrzewa G; Kruk M; Płoski R; Witkowski A; Rużyłło W
    Cardiology; 2010; 117(2):81-7. PubMed ID: 20924183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
    Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
    Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dörrler K; Morath T; Schömig A; Kastrati A; von Beckerath N
    Eur Heart J; 2009 Apr; 30(8):916-22. PubMed ID: 19193675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
    Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
    Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
    JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Bhattacharyya S; Rakhit R
    Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
    Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
    J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
    Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
    PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
    Galiavich AS; Valeeva DD; Minnetdinov RSh; Arkhipova AA; Akhmetov II; Galiavi RA
    Kardiologiia; 2012; 52(4):20-4. PubMed ID: 22839512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.